Search Results

You are looking at 81 - 90 of 385 items for :

  • "bevacizumab" x
  • Refine by Access: All x
Clear All
Full access

Maintenance Chemotherapy in Non–Small Cell Lung Cancer

Keith D. Eaton and Renato G. Martins

growth factor receptor (EGFR) to chemotherapy, 7 and the incorporation of other non-chemotherapy agents 8 all failed to improve survival and QOL. Recently, the addition of the anti–vascular endothelial growth factor (VEGF) antibody bevacizumab

Full access

Oncology Research Program

Bevacizumab Added Concurrently to Chemotherapy for Palpable and Operable Triple-Negative Invasive Breast Cancer Principal Investigator: Jasgit C. Sachdev, MD Condition: Triple-negative breast cancer Institutions: University of Tennessee Cancer

Full access

Management of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancers

Presented by: Joyce F. Liu

benefit from bevacizumab? Is testing for homologous recombination deficiency (HRD)/genomic instability appropriate? What is the role of maintenance therapy with PARP inhibitors? Of note, because the treatment of advanced ovarian cancer is complex and

Full access

Oncology Research Program

Carboplatin Followed By Doxorubicin Plus Cyclophosphamide With Bevacizumab Added Concurrently to Chemotherapy for Palpable and Operable Triple Negative Invasive Breast Cancer Principal Investigator: Jasgit C. Sachdev, MD Condition: Triple negative breast

Full access

HSR21-065: Oncologists’ Perceptions and Utilization of Therapeutic Oncology Biosimilars in the U.S.

Sonia Oskouei, Amy Graham Russell, Yolaine Jeune-Smith, and Ajeet Gajra

critical therapies with the potential to lower cost of care. There are 9 FDA approved therapeutic oncology biosimilars to 3 reference molecules: trastuzumab (5), bevacizumab (2) and rituximab (2), in addition to supportive care biosimilars for hematopoietic

Full access

Management of Recurrent or Metastatic Cervical Cancer

Presented by: Nadeem R. Abu-Rustum

as bevacizumab and pembrolizumab is difficult in this patient population, because bevacizumab and pembrolizumab are not widely available, are expensive, and require specific expertise to be delivered. Despite their improved activity over traditional

Full access

HSR22-145: Pembrolizumab Plus Chemotherapy for First-Line Treatment of Advanced Triple-Negative Breast Cancer – A Network Meta-Analysis

Amin Haiderali, Min Huang, Wilbur Pan, Grace Fox, Dylan Maciel, and Andrew Frederickson

nab-paclitaxel for PFS. Statistical superiority was also reported for pembrolizumab+paclitaxel compared to paclitaxel (for OS and PFS), paclitaxel+ bevacizumab (for OS) and ixabepilone+bevacizumab (for OS). Conclusions : These analyses suggest

Full access

Advances in the Treatment of Non-Small Cell Lung Cancer

Leora Horn

guidelines, maintenance therapy is an option for select patients with tumor response or stable disease and is not considered the standard of care for all patients. Category 1 options in continuation maintenance therapy include single-agent bevacizumab and

Full access

Oncology Research Program

Bendamustine and Bevacizumab for Patients With Advanced Cancers Principal Investigator: Apostolia M. Tsimberidou, MD, PhD Condition: Advanced cancers Institution: The University of Texas MD Anderson Cancer Center, Houston, Texas Bendamustine is

Full access

Emerging Treatment Options for the Management of Metastatic Colorectal Cancer

Presented by: Dustin A. Deming

molecular features of the tumor. Across the continuum of treatment, patients usually received FOLFOX (5-FU/leucovorin/oxaliplatin) and/or FOLFIRI (5-FU/leucovorin/irinotecan) ± bevacizumab and an agent targeting the epidermal growth factor receptor (EGFR